// App-Quantinova.ai

: Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Researchers

Presenter

  • Tara Elisabeth Seery

Principal Investigators

  • Chaitali Singh Nangia

  • Phillip D. Reid

  • Bruno Fang

  • Heidi Ann McKean

  • Leonard S. Sender

  • Sandeep K. Reddy

  • Patrick Soon-Shiong

Medical Centers

  • Avera Medical Group Oncology & Hematology, Sioux Falls, SD

  • Astera Cancer Care, East Brunswick, NJ

  • Hoag Cancer Center, Newport Beach, CA

  • ImmunityBio, LLC, Culver City, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreato-biliary malignancies

Biomarkers

  • Programmed death-ligand 1

  • Granulocyte colony-stimulating factor

  • Interleukin-15

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • INNO206

  • Gemcitabine

  • Paclitaxel

  • Inbakicept

  • Filgrastim

  • IL-15

Outcome

  • N/A

Study Design

  • Adaptive

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03563144

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved